Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

SUMMARY: In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent reductions in bone turnover markers. Denosumab treatment was well tolerated throughout the 8-year study. INTRODUCTION: The purpose of this study is...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer-Verlag 2012
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3536967/
https://ncbi.nlm.nih.gov/pubmed/22776860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-012-2052-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы